<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811326</url>
  </required_header>
  <id_info>
    <org_study_id>504/1/21</org_study_id>
    <nct_id>NCT04811326</nct_id>
  </id_info>
  <brief_title>Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation</brief_title>
  <official_title>Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaimaa Fawzy Abdel-rady Abdel-latif</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the efficacy of different lines of therapies on the TWEAK&#xD;
      serum level in patients with non-segmental vitiligo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the study is to evaluate the efficacy of NB-UVB, latanoprost, and combination of them on the&#xD;
      TWEAK serum level in patients with non-segmental vitiligo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">September 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum TWEAK in vitiligo</measure>
    <time_frame>3months</time_frame>
    <description>measurement of serum Tumor necrosis factor weak inducer of apoptosis (TWEAK)&quot;pg/ml&quot;; in vitiligo patients before and after treatment with NB-UVB, Latanoprost and their combination, all in comparison with healthy individuals, using ELISA (enzyme-linked immunosorbent assay)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment of vitiligo</measure>
    <time_frame>3 months</time_frame>
    <description>clinical evaluation: Assessment of the disease severity in non-segmental vitiligo will be performed by using vitiligo area severity index (VASI score) before and after treatment with NB-UVB, latanoprost application applied after microneedling, by using 1.5-2 mm needle length dermapen, of vitiligenous patches, or combination of both of them. Patients will be photographed at baseline and after 3 months of regular treatment by using high resolution digital camera conon EOS 1300D 18 megapixels (made in Taiwan), photography will be done in standard light and distance.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Non-segmental Vitiligo</condition>
  <arm_group>
    <arm_group_label>NB-UVB radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will expose to 2 sessions/week of NB-UVB radiation, for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>latanoprost 0.005%, will be applied after microneedling, by using 1.5-2 mm needle length dermapen, of vitiligenous patches. The procedure will be repeated once weekly for 3 months (12 sessions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>latanoprost + NB-UVB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(latanoprost + NB-UVB group): latanoprost 0.005%, will be applied after microneedling of vitiligenous patches in the same day of NB-UVB sessions in the same manner of group 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy individuals</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>healthy individuals as control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>NB-UVB</intervention_name>
    <description>radiation</description>
    <arm_group_label>NB-UVB radiation</arm_group_label>
    <arm_group_label>latanoprost + NB-UVB</arm_group_label>
    <other_name>narrow band ultraviolet B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>eye drops</description>
    <arm_group_label>Latanoprost</arm_group_label>
    <arm_group_label>latanoprost + NB-UVB</arm_group_label>
    <other_name>latanoprost eye drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with non-segmental vitiligo of any age and gender.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of vitiligo treatment with topical, systemic or biological agents prior to the&#xD;
             study for at least 3 weeks.&#xD;
&#xD;
          -  Pregnancy and lactation.&#xD;
&#xD;
          -  Infections&#xD;
&#xD;
          -  Patients with other autoimmune diseases.&#xD;
&#xD;
          -  Patients with chronic diseases: cardiac diseases, hepatic disorders, hematologic&#xD;
             disease, chronic renal failure or malignancies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moustafa A El Taieb, prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Prof. and Head of Dermatology, Venereology and Andrology department, Aswan University, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>faculty of medicine, Aswan University</name>
      <address>
        <city>Aswan</city>
        <state>Aswan Governorate</state>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 7, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>Shaimaa Fawzy Abdel-rady Abdel-latif</investigator_full_name>
    <investigator_title>investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

